AAIC 2025 Abstract
The HOPE4MCI study: AGB101 treatment normalizes aberrant network activity and slows entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriers
Trial in peopleInterventions
Abstract
Background: Hippocampal hyperactivity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for AD progression and clinical cognitive worsening in amnestic mild cognitive impairment (aMCI).
